"Thrombopoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humoral factor that stimulates the production of thrombocytes (BLOOD PLATELETS). Thrombopoietin stimulates the proliferation of bone marrow MEGAKARYOCYTES and their release of blood platelets. The process is called THROMBOPOIESIS.
| Descriptor ID |
D013926
|
| MeSH Number(s) |
D12.644.276.374.410.240.750 D12.776.395.240.750 D12.776.467.374.410.240.750 D23.529.374.410.240.750
|
| Concept/Terms |
Thrombopoietin- Thrombopoietin
- Megakaryocyte Colony Stimulating Factor
- Megakaryocyte Growth and Development Factor
- Thrombocytopoietin
- mpl Ligand
- Ligand, mpl
- Myeloproliferative Leukemia Virus Oncogene Ligand
- Thrombocytopoiesis-Stimulating Factor
- Thrombocytopoiesis Stimulating Factor
- c-mpl Ligand
- Ligand, c-mpl
- MGDF Factor
|
Below are MeSH descriptors whose meaning is more general than "Thrombopoietin".
Below are MeSH descriptors whose meaning is more specific than "Thrombopoietin".
This graph shows the total number of publications written about "Thrombopoietin" by people in this website by year, and whether "Thrombopoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thrombopoietin" by people in Profiles.
-
Megakaryocyte/platelet-derived TGF-ß1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver. Blood Adv. 2022 06 14; 6(11):3321-3328.
-
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS One. 2020; 15(6):e0232801.
-
Erythropoietin and thrombopoietin mimetics: Natural alternatives to erythrocyte and platelet disorders. Crit Rev Oncol Hematol. 2016 Dec; 108:175-186.
-
Complete remission of refractory immune thrombocytopenia (ITP) with a short course of Romiplostim. Eur J Haematol. 2013 Oct; 91(4):376-7.
-
Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics. Hematology Am Soc Hematol Educ Program. 2012; 2012:444-9.
-
Children with ITP: looking beyond the platelet count. Pediatr Blood Cancer. 2012 Mar; 58(3):323-4.
-
Management of immune thrombocytopenia--something old, something new. N Engl J Med. 2010 Nov 11; 363(20):1959-61.
-
Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patients. Am J Hematol. 2009 Jul; 84(7):459-61.
-
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009 Feb; 144(3):409-15.
-
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008 May 15; 111(10):5109-17.